Enterprise Value

8.284B

Cash

894.6M

Avg Qtr Burn

N/A

Short % of Float

3.33%

Insider Ownership

1.06%

Institutional Own.

95.26%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
INGREZZA (valbenazine) Details
Huntington's disease, Dyskinesia

Approved

Quarterly sales

Valbenazine Details
Huntington's disease

PDUFA

Approval decision

Valbenazine Details
Dyskinesia due to Cerebral Palsy

Phase 3

Data readout

Crinecerfont Details
Congenital adrenal hyperplasia

Phase 3

Data readout

Valbenazine Details
Psychiatric disorder, Schizophrenia

Phase 2

Data readout

NBI-1065846 Details
Major depressive disorder

Phase 2

Data readout

NBI-921352 Details
Focal Onset Seizures

Phase 2

Data readout